vector icon vector icon
Back
Message sent successfully
vector

About Us

Located in Haifa, in the heart of Northern Israel, Nurami Medical Ltd. is rewriting the narrative of soft tissue regeneration. Founded by Nora Nseir and Dr. Amir Bahar, the company's journey began in a modest facility, where they envisioned a solution to the challenges plaguing surgical procedures.
About Us
figure figure vector

Our Story

Our story

Their brainchild, ArtiFascia®, the world's first multilayer Dural substitute, symbolizes Nurami's commitment to modernizing soft tissue repair. Fueled by a revolutionary spirit, the company leverages nanotechnology and novel biomaterials, developing surgical sealants and grafts that transcend traditional limitations.

Our story

Key to Nurami's innovation are nanofibers – delicate strands of bioresorbable polymers that mimic the natural extracellular matrix and accelerate tissue healing. This multifunctional approach represents a paradigm shift in soft tissue regeneration.

Our story

Nurami's story is told by a diverse team of professionals, each contributing to the narrative of resilience and excellence. From engineers and managers to R&D, operations, QA, BD, marketing, clinical trials, and management, this team orchestrates a symphony of expertise.

In the unfolding narrative of Nurami, every product is a chapter, showcasing the company's dedication to rewriting the possibilities in medical innovation. This Israeli trailblazer is not just a medical device company – it is a storyteller, painting a healthier future for patients worldwide.

figure

Milestones

2014
Nurami was founded by Nora Nseir and Dr. Amir Bahar
2014
2016
IP applications
2016
2020
Pivotal clinical trials initiation
2020
2022
Establishment of new facility and cleanroom production
2022
2023
FDA clearance obtained for ArtiFascia®
2023
2024
Initial commercialization
2024

Team

Nurami boasts a strong multi-disciplinary team of experienced engineers and managers that is composed by professionals in the fields of R&D, operations, production, QA, BD, marketing, clinical trials and management. 

Hannoch Marksheid
Hannoch Marksheid
Co-CEO
Hannoch Marksheid is a seasoned manager, with over 25 years of experience in managing entrepreneurial ventures in multi-cultural environments including biotechnological startups. Hannoch brings extensive experience in senior and executive management, fundraising, and global business development. He is an expert in strategic planning, process implementation and program development with extensive experience in fundraising from angels, corporates, corporate funds, and the venture capital community, as well as in raising non-diluting grants and debt instruments. Hannoch holds a PhD in economics and business management.
Nora Nseir
Nora Nseir
Founder, Co-CEO, and CTO
Nora brings a proven entrepreneurial and executive experience in the healthcare industry. She holds a M.Sc. in regenerative medicine from the Technion and is highly experienced in developing and leading development of nanofiber based medical devices, biomaterials, nanotechnology and regenerative medicine. Nora was among the finalists of the EU women innovators prize in 2019. In 2021, 2018 & 2017, she was included in Globes “Women of Influence” list. Nora co-founded the Arab-Women-in-Science NGO which promotes women in STEM.
Dr. Amir Bahar
Dr. Amir Bahar
Founder and COO
Dr. Amir Bahar is a multidisciplinary entrepreneur and neuroscientist with over 25 years of experience in clinical and preclinical models of brain research and tissue engineering. Amir brings extensive experience in management of R&D, regulation, clinical operation, production under ISO13485 and operation in general, with a focus on degradable implants and nanofibers. He is highly experienced in leading early and advanced R&D and clinical projects in medical devices, degradable implants and nanofibers. Amir received his Ph.D. in neurobiology from the Weizmann Institute and won a NARSAD Young Investigator Award (2008).
Peter Stebbins
Peter Stebbins
Executive Chairperson
Peter is a business development and operating executive who is well-established in the MedTech ecosystem. His impressive career includes a distinguished run at J&J, where he led diverse roles across the Ethicon (surgical) and Depuy Synthes/Codman (ortho/neuro) markets and evaluated, bought, built, sold, and nurtured companies. He holds a BS Eng. in chemical engineering from Princeton and an MBA from Harvard.
Koby Gvili
Koby Gvili
VP R&D
Dr. Koby Gvili is a biomaterial expert with extensive experience in R&D and Operations positions in medical device companies developing: cartilage and bone regeneration hydrogel, transgenic collagen, and dermal fillers. As the CEO of a project management company, Dr. Gvili managed over 40 projects for the biomedical industry in Israel and abroad in numerous fields including regenerative medicine, cardiology, diabetes, gynecology, drug and cannabinoid delivery. Koby holds a B.Sc.in Chemical Engineering (BGU university) and a Ph.D. in Biotechnology Engineering (Technion), focused on nanoparticle-based DNA vaccination.
Dana Barocas
Dana Barocas
VP of Commercialization
Dana is a business executive with over 15 years of experience in the medical industry in various managerial roles from product manager, business development, marketing and strategy to head of business unit and commercial direction. Dana brings extensive experience in international markets along with multicultural and multilingual capabilities. She holds a BA in international relations and an MBA in business communication, both from the State University of Milan, Italy.
Dr. Joseph Milbaum
Dr. Joseph Milbaum
Medical Director
Dr. Milbaum graduated from the Sackler Medical School at Tel Aviv University in 1996 and holds a bachelor degree in material science and engineering from Ben Gurion University. He is an active surgeon at the Meir Medical Center with extensive experience in trauma and emergency medicine. Dr. Milbaum has over 15 years’ experience as a Medical Director in the medical device industry. He has managed several pre-clinical and clinical studies, including for a class III device.
Rachel Leibovitze
Rachel Leibovitze
Director of Business Development and Strategy
Rachel Leibovitze is a seasoned business development and strategy consultant, with extensive experience in market analysis, strategy creation and business development. She has worked with many biotech and medical device companies, helping them formulate their go to market strategies and gain in depth understanding of the competitive environment. As former BD manager at a biotech startup, she has experience in identifying potential strategic partners and building collaboration relationships. Rachel holds a BA in economics and business management from Bar Ilan University and an MBA from Tel Aviv University.
Alon Galili
Alon Galili
QA Manager
Alon Galili is Quality Assurance specialist with over 20 years of experience in the medical devices and biotechnology industries, including in management roles.
Alon brings extensive experience in establishing and maintaining quality management systems, documentation control, validations
and a variety of quality processes, in addition to extensive knowledge of EU, QSR, GDP and GMP requirements.
Dr. Malca Chen-Zion
Dr. Malca Chen-Zion
Regulatory Affairs
Dr. Chen-Zion brings over two decades of experience in the fields of regulatory affairs, preclinical research and clinical trials of medical devices and biotechnology. She has vast experience in leading all regulatory process towards international product approval. Dr. Chen-Zion holds a Ph.D. in biology from Bar-Ilan University.
Jonathan Harari
Jonathan Harari
QA Specialist
Jonathan Harari is an expert documentation specialist with significant experience in establishing quality management systems, and submitting regulatory documents for companies in the medical device industry. His expertise encompasses medical device documentation, quality management, product lifecycles, design control documentation, extensive knowledge of EU, QSR, GLP, GDP and GMP requirements, submissions to both the CE and FDA and spearheading product development from concept to commercialization.

Scientific Advisory Board

Prof. Michael Schulder
Prof. Michael Schulder
M.D.
Prof. Schulder serves as the Vice Chairman of the Department of Neurosurgery and Director of the Brain Tumor Center at the Hofstra Northwell School of Medicine, Manhasset, NY.
Dr. Schulder has been named as one of the top doctors in the New York metropolitan area annually for over a decade. In addition, he is an internationally recognized expert in the use of stereotactic methods to treat patients with brain tumors.
Prof. Schulder has authored more than 70 peer-reviewed articles, 31 abstracts, 17 book chapters and over 200 presentations at national and international meetings. He has received the Leonard Tow Award for Humanism in Medicine and has been elected to the Gold Humanism Honors Society.
Prof. Henry Brem
Prof. Henry Brem
M.D.
Dr. Henry Brem is the Harvey Cushing Professor of Neurosurgery at The Johns Hopkins University, Director of the Department of Neurosurgery, and Neurosurgeon-in-Chief. He is a professor of Oncology, Ophthalmology, and Biomedical Engineering and co-leads the Brain Cancer Program for the Johns Hopkins Kimmel Cancer Center. Dr. Brem has built collaborative neurosurgical programs in the Washington Capital region and facilitated Hopkins’ Neurosurgery programs in many countries throughout the world.
Dr. Brem has revolutionized surgical treatment of brain tumors by introducing new approaches for targeted therapy. He developed new classes of polymers and microchips for drug delivery that are custom synthesized for the agent being developed. The polyanhydrides, which were the first new treatments for brain tumors that the FDA had approved in 23 years, have been shown in his laboratory to be biocompatible and potent.
Prof. Andrew Kaye
Prof. Andrew Kaye
M.D.
Professor Kaye is a Professor of Surgery, and has acted as Head of the Department of Surgery (RMH) at The University of Melbourne and Head of the Department of Neurosurgery at The Royal Melbourne Hospital. He is also the President of the Asian Australasian Society of Neurological Surgeons. Prof. Kaye was the foundation Editor-in-Chief of the Journal of Clinical Neuroscience. He has authored and co-authored over 150 journal articles and book chapters, as well as five books including “Brain Tumors” (co-author), a text recognized as being the definitive work on the subject.
Dr. Sagi Harnof
Dr. Sagi Harnof
M.D.
Dr. Harnof is a senior neurosurgeon and the Head of the Neurosurgery Department at Rabin Medical Center, Petach Tikwa, the 3rd largest hospital in Israel. He specializes in cerebral-vasculature and in brain tumor surgeries. Dr. Harnof received his MD. from Tel-Aviv University. He is involved in many pre-clinical and clinical studies in several fields, as well as in various research projects at different research centers in the EU and the US.
Prof. Eyal Zussman
Prof. Eyal Zussman
Ph.D.
Prof. Zussman has been at the Department of Mechanical Engineering, Technion – Israel Institute of Technology since 1994. He received his doctor’s degree in mechanical engineering from the Technion. His research includes polymer processing, electrospinning, and materials characterization. Prof. Zussman has been active in biomedical applications aiming at developing dental membranes, biodegradable extra cellular matrix (ECM), and drug delivery systems all based on electrospun fibers. He has published more than 100 journal publications and holds over 10 patents.
Dr. Michael Groff
Dr. Michael Groff
Ph.D.
Michael W. Groff, M.D. is the Vice-Chairman and Director of Spinal Neurosurgery at the Brigham and Women’s Hospital. He earned his MD at the University of Pittsburgh and then went on to the Mount Sinai Hospital in New York for internship and residency training in neurological surgery. He completed his training at the Medical College of Wisconsin with a fellowship in spinal surgery.
Dr. Groff is a former Chairman of the Joint Section of the Spine and Peripheral Nerves of the AANS/CNS, the national neurosurgical spine organization. He is also active in the American Association of Neurological Surgeons (AANS) and serves as the Vice-Chairman of the Neurosurgery Research and Education Foundation (NREF). He serves as the Co-Chair on the editorial board for the Journal of Neurosurgery: Spine, as well as Neurosurgery, World Neurosurgery, and Clinical Neurology and Neurosurgery.

Contact us

Israel
USA
Nurami Medical Ltd. HQ
Israel
Nurami Medical Ltd. HQ
36 Ha-Namal St., Haifa, Israel
Nurami Medical INC.
USA
Nurami Medical Inc.
2436 Emrick Boulevard,
Bethlehem, PA 18020, USA
Message sent successfully
Skip to content